{"id":"kc1036","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"While the exact molecular target of KC1036 has not been publicly disclosed in detail, it is being developed by Beijing Konruns Pharmaceutical as an oncology therapeutic in Phase 3 clinical trials. The drug likely functions by inhibiting aberrant signaling pathways that drive tumor growth, though the specific kinase target and mechanism require further public disclosure.","oneSentence":"KC1036 is a small molecule inhibitor targeting a specific kinase involved in cancer cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:51.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT05683886","phase":"PHASE2","title":"A Study of KC1036 in Patients with Advanced Thymic Tumors","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2023-02-22","conditions":"Thymic Tumors","enrollment":30},{"nctId":"NCT05260385","phase":"PHASE1, PHASE2","title":"To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2022-01-24","conditions":"Digestive System Tumors","enrollment":133},{"nctId":"NCT04387916","phase":"PHASE1","title":"A Study of KC1036 in Patients with Advanced Solid Tumors","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2020-09-04","conditions":"Advanced Solid Tumors","enrollment":207},{"nctId":"NCT06564272","phase":"PHASE2","title":"A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2024-09-27","conditions":"Ewing Sarcoma","enrollment":30},{"nctId":"NCT06194734","phase":"PHASE3","title":"A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2024-02-05","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":490},{"nctId":"NCT05265338","phase":"NA","title":"A Food Effect Study of KC1036 in Healthy Subjects","status":"COMPLETED","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2022-03-10","conditions":"Healthy Subjects","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KC1036","genericName":"KC1036","companyName":"Beijing Konruns Pharmaceutical Co., Ltd.","companyId":"beijing-konruns-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}